Recent developments

at Tullis and our portfolio companies

News

Keeping you current on new and follow-on investments, portfolio product and service milestones, publications and events, management and board transitions, and other developments in Tullis funds.

November

3

electroCore Announces Third Quarter 2022 Financial Results

Third quarter 2022 revenue grew 33% over third quarter 2021 ROCKAWAY, N.J. , Nov. 03, 2022 (GLOBE NEWSWIRE) —...

1

electroCore, Inc. Announces Distribution Agreement with Joerns Healthcare, LLC

ROCKAWAY, N.J., Nov. 01, 2022 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company,...

4

electroCore Announces Record Second Quarter 2022 Financial Results

Record second quarter 2022 net sales of $2.2 million, increased 70% over second quarter 2021 and...

12

electroCore Provides Select Second Quarter 2022 Financial Guidance

Record revenue will be at least $2.1 million; approximately 65% growth over second quarter 2021 June...

24

electroCore, Inc. Announces gammaCore™ Non-Invasive Vagus Nerve Stimulator Available Through National Spine and Pain Centers

ROCKAWAY, N.J., May 24, 2022 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company,...

14

electroCore Announces Regulatory Approval in Canada to Treat Adolescent Migraine

Health Canada expands gammaCore label to include the acute and preventive treatment of migraine...

5

electroCore Announces Second Quarter 2021 Financial Results

Second quarter 2021 net sales of $1.3 million, increased 69% over second quarter 2020...

27

electroCore Announces Issuance of New Patent for Migraine Treatment Using Smartphones

Newly allowed patent is latest U.S. patent to issue in connection with electroCore’s non-invasive development program...

13

electroCore Provides Business Update and Select Second Quarter 2021 Financial Guidance

Second-Quarter 2021 revenue expected to be approximately $1.3 million Net cash used to fund operations in the second quarter...

28

electroCore Inc. Announces Exclusive Distribution Agreement with Medistar Following Regulatory Approval in Australia

Australian Therapeutic Goods Administration approved gammaCore Sapphire family of products ROCKAWAY, N.J., Feb. 28, 2021 (GLOBE NEWSWIRE)...

26

electroCore, Inc. Announces Exclusive Distribution Agreement with RSK Medical Inc. in Canada

RSK Medical will serve as exclusive distributor of the gammaCore Sapphire™ in Canada, supplying therapy...

21

electroCore, Inc. Announces Agreement with Pro Medical Baltic to be Exclusive Distributor for gammaCore Sapphire™ in Eastern Europe

Agreement covers Lithuania, Latvia, Belarus, Kazakhstan and Ukraine ROCKAWAY, N.J., Dec. 21, 2020 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic...

Recent developments

News

November

3

electroCore Announces Third Quarter 2022 Financial Results

November

1

electroCore, Inc. Announces Distribution Agreement with Joerns Healthcare, LLC

August

4

electroCore Announces Record Second Quarter 2022 Financial Results

July

12

electroCore Provides Select Second Quarter 2022 Financial Guidance

May

24

electroCore, Inc. Announces gammaCore™ Non-Invasive Vagus Nerve Stimulator Available Through National Spine and Pain Centers

October

14

electroCore Announces Regulatory Approval in Canada to Treat Adolescent Migraine

August

5

electroCore Announces Second Quarter 2021 Financial Results

July

27

electroCore Announces Issuance of New Patent for Migraine Treatment Using Smartphones

July

13

electroCore Provides Business Update and Select Second Quarter 2021 Financial Guidance

February

28

electroCore Inc. Announces Exclusive Distribution Agreement with Medistar Following Regulatory Approval in Australia

January

26

electroCore, Inc. Announces Exclusive Distribution Agreement with RSK Medical Inc. in Canada

December

21

electroCore, Inc. Announces Agreement with Pro Medical Baltic to be Exclusive Distributor for gammaCore Sapphire™ in Eastern Europe